

## Technology Advisory Committee B Interests Register

### Baricitinib for treating moderate to severe atopic dermatitis [ID1622]

Publication Date: 3 March 2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Andrew Pink	Clinical expert	Direct financial interests	Advisor and speaker for Eli Lilly & Company	NA	12/05/20/20	NA	It was agreed that this declaration would not prevent Dr Pink from participating in this section of the meeting.
Dr Andrew Pink	Clinical expert	Direct non-financial interests	Acted as PI on Eli Lilly clinical trials & Company	NA	12/05/20/20	NA	It was agreed that this declaration would not prevent Dr Pink from participating in this section of the meeting.
Dr Richard Weller	Clinical expert	Direct financial interests	Served on an advisory panel for Lilly for which payment was received.	NA	20/05/2020	NA	It was agreed that this declaration would not prevent Dr Weller from participating in this section of the meeting.
Alice Lambert	Patient expert	Indirect interests	Worked at the National Eczema Society since 19 June 2017 and has worked as a corporate sponsor of Eli Lilly since 2019.	NA	17/07/2020	NA	It was agreed that these declarations would not prevent Alice from participating in this section of the meeting.